HOME > FOR BUSINESS > R&D projects > R&D at IBB PAS

R&D Projects at IBB PAN

Centre of biotechnology medical products.


 Package of innovative biopharmaceuticals for human and animal therapy and prophylactics

Budget: 27.000.000 USD (IBB PAS - 2.400.000 USD); EU participation: 22.900.000 USD (IBB PAS - 2.000.000 USD);

Period: 01.03.2008-31.12.2011; Contract number: POIG.01.01.02-00-007/08

Two teams from IBB PAS, together with some other Polish research institutions, participate in the Project coordinated by the Institute of Biotechnology and Antibiotics from Warsaw. Three workpackages are realized in IBB PAS. Two of them focus on elaboration of a vaccine for poultry against bird flu, while the third one deals with construction of gene- and immune-sensors for detection of the H5N1 virus. The constructed vaccine is based on the DNA coding for a strong antigen of the Polish viral isolate A/swan/Poland/305/2006 H5N1; in the second approach the viral antigen will be produced by lactic acid bacteria and applied in tests as an oral vaccine. In this respect, a safe and novel vaccine demonstrating a tightly defined composition, which will allow to distinguish vaccinated birds from those infected (DIVA strategy - Differentiation of Infected from Vaccinated Animals) with the use of adequate diagnostic tests. The third workpackage is performed in collaboration with the team headed by prof. Jerzy Radecki (IRZiB – PAN from Olsztyn). In these studies an innovative approach of detecting the bird flu virus has been applied to design and construct specific probes that can be applied in field trials.


Optimization of characteristic and production of phage preparations for therapeutic purposes

Budget: 4.100.000 USD (IBB PAS - 1.970.000 USD); EU participation: 3.500.000 USD (IBB PAS - 1.680.000);

Period: 01.03.2008-30.04.2012; Contract number: POIG.01.03.01-00-003/08

This project is performed by the consortium of three institutions. The project beneficiary and the consortium leader is Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, PAS. The aim of the project is the development of fully characterized and safe preparations of obligatorily virulent bacteriophages against selected pathogens. The preparations obtained will serve to study the efficacy of bacteriophage therapy of human and animal infections and will be a starting material to prepare phage mixtures for clinical trials and development of new therapeutic agents. IBB PAS is responsible for: genomic characteristics and specificity determination of 5 polyvalent bacteriophages of the therapeutic preparation against Staphylococcus aureus; 5-7-bacteriophages of the therapeutic preparation against Pseudomonas, and 7-9 bacteriophages of the therapeutic preparation against Enterococcus. Additionally, new lytic enzymes of the above mentioned bacteriophages will be identified.


Application of polyisoprenoid derivatives as drug carriers and metabolism modulators

Budget: 1.500.000 USD; EU participation: 1.275.000 USD; Period: 01.01.2010-31.01.2014 Contract number: UDA-POIG.01.03.01-14-036/09-00

This project is performed by the consortium of 7 institutions. IBB PAS is the project's coordinator. The aim of the project is to develop new procedures of preparation of new types of compounds suitable for pharmaceutical and cosmetic industry as well as for producers of biochemicals for laboratory use. These are: (i) methods of preparation of new drug carrying vesicles (liposomes which facilitate the transfer of drugs and genetic material into a cell) containing trimethylammonium salts of polyisoprenoids; (ii) protocols which enhance pharmacological applications of epoxidated polyisoprenoids. Two types of potential products are expected, tested in laboratory conditions with in vitro and in vivo models. Formulas are tested of liposomal vesicles applicable as drug carriers and recipes of metabolism modulating semisynthetic compounds. 


Engineering of Trichoderma strains with enhanced biocontrol properties

Budget: 950.000 USD; EU participation: 800.000 USD;

Period: 01.03.2009-31.12.2012; Contract number: UDA-POIG.01.03.01-14-038/09-00

Antagonism of Trichoderma against phytopathogenic fungi is widely exploited for biocontrol of plant diseases. A crucial role in the biocontrol mechanism is attributed to cell wall degrading enzymes secreted by Trichoderma. More efficient production and secretion of the enzymes should therefore elevate the biocontrol abilities of Trichoderma. Since the majority of secretory hydrolases are glycoproteins, it has been postulated that the posttranslational modification of these proteins could constitute a bottle neck in their production and secretion and/or their activity. In this project we concentrate not only on the intensive synthesis and secretion of hydrolytic enzymes but also on the secondary metabolites such as potential antibiotics, terpenes, polypeptides, pyrones, all of mycotoxic activity. The aim of the project is to enhance the production of all compounds engaged in the direct attack of biocontrol agent on the pathogenic fungi. In general, profits from the use of such a biocontrol agent are evident and mainly connected with the limitation of losses in agriculture and wildlife conservation.


Development of methods for genetic marker identification in predisposition to insulin resistance

Budget: 6.000.000 USD (IBB PAN - 1.120.000 USD); EU participation: 5.100.000 USD (IBB PAN - 960.000 USD);

Period: 01.04.2009-10.07.2014Contract number: POIG.01.03.01-00-128/08-00

The Project is coordinated by the Clinical Department of Endocrinology, Diabetology and Internal Diseases, USK in Białystok. The project is aimed at creating the proteomic and genomic data sets for selected number of nondiabetic patients leading to early identification of people with insulin resistance. Collected data will be used for discovering proteomic and transciptomic-based new biomarkers for detecting predisposition to metabolic disorders. The final goals of the project:

1. Creation of the new medical tests which could help to diagnose early stages of insulin resistance related disorders;

2. Based on the results of the project personalization of medical treatment for patients with insulin resistance;

3. Discovering and indicating new therapeutic targets, establishing new medical therapiesElectrochemical biosensors for detection of activation of RAGE receptors – tools of cheap teranostics


Electrochemical biosensors for detection of activation of RAGE receptors-tools of cheap teranostics

Budget: 3 471 281,79 PLN; EU participation: 2 950 589,52 PLN

Period: 01.04.2009-31.12.2013; Contract number: POIG.01.01.02-00-048/09-00

This project is performed in the cooperation with the Institute of Animal Reproduction and Food Research PAS, Olsztyn. IBB PAS is the project's coordinator. The aim of the project is to design, construct and verify the work of laboratory prototypes of a family of electrochemical biosensors enabling detection of pathological activation of RAGE receptors by their endogenous ligands. This family of biosensors will provide a new, economically viable tool aiding the theranostics of several diseases of a large socioeconomic impact. Product: Laboratory prototypes of electrochemical sensors detecting initial stages of RAGE receptor mediated diseases.


Metagenomics-a source of new tools for enzymatic bioremediation and biotransformation

Budget: 15 225 200,27 PL; EU participation: 12 941 420,22 PLN;

Period: 01.04.2009-31.12.2010; Contract number: POIG.01.01.02-14-054/09-00

The aim of this project is to use metagenomics - a culture-independent methodology, to screen genomes of soil prokaryotes for enzymes showing potential features as new bioremediation and biotransformation tools. Implementation of second generation sequencing, advanced bioinformatic approach and large-scale protein purification methods allow to obtain formulated enzymes suitable for analysis of their catalytic abilities. For the most promising proteins, genetic engineering is applied to maximize their enzymatic potential, stability and a manufacturing process. As a final step we are going to perform field tests of selected enzymes. The project is conducted by Institute of Biochemistry and Biophysics PAS in cooperation with Interdisciplinary Centre for Mathematical and Computational Modelling. Warsaw University and Institute of Organic Chemistry PAS.


Innovative probiotic with anti-allergic functions

Budget: 2 650 000 PLN;

Contract number: N R 12 0101 10

Responding to the food and feeding priorities of the EU IBB PAS with the cooperation with the Institute of Fermentation Technology and Microbiology of ŁódźŸ Technical University, the Children's Memorial Health Institute in Warsaw and Gnobiotic Department of Czech Academy of Sciences undertook integrated R&D activities to develop a probiotic product dedicated for anti-allergic applications.


Method of recombinant protein purification based on a novel affinity tag cleavage reaction

Budget: 1 226 000 PLN;

Contract number: KB/138/13749/IT1-B/U/08

A method of recombinant protein purification based on a novel affinity tag cleavage reaction. C-terminal tags, such as His-tag, expanded by a specific hexapeptide domain, are conveniently cleaved off in a protease-free manner in a buffer containing Ni(II) ions. Very pure native sequence proteins are obtained in this fashion at a low cost and a very high yield > 90%. Two options are available: the tag can be cleaved off in solution or directly on the affinity column. The latter approach is particularly promising, as it offers a very simple purification procedure.


Adenovirus dodecahedron as a delivery platform for antigens development of a novel influenza vaccine

Budget: 550 000 PLN;

Contract number: N N302 505738, 2010-2013;

The aim of the project is construction and characterization of a novel influenza vaccine in which viral antigens are delivered on a platform of a virus-like particle, adenovirus dodecahedron. Dodecahedron (Dd) is a symmetrical particle made of 12 copies of adenovirus penton base that is characterized by remarkable effectiveness of intracellular entry. Two influenza antigens are used in vaccine design: genetically unstable external influenza hemagglutinin (HA), which confers humoral immunity and a more conserved internal matrix protein 1 (M1), which might confer cellular immunity. The vaccine is obtained by expression in the baculovirus system. We have shown that the noncovalent complex of Dd with influenza M1 protein is effectively internalized by human myeloid dendritic cells (MDC) in vitro, induces their maturation and is efficiently presented by MDC to antigen-specific CD8+ T lymphocytes. In the next steps we plan to construct the vaccine combining both antigens and investigate the potential of our new vaccine to protect against influenza challenge in an animal model. Dodecahedric VLP platform should act as adjuvant, and together with multivalently displayed antigens will induce an effective protection against heterologous influenza strains. Studies on vaccine efficacy - T cells activation, are conducted in cooperation with Laboratory of Immunobiology and Immunotherapy, Research Center Albert Bonniot, France.


BioCentrum Ochota

Instytut Biochemii i Biofizyki PAN Instytut Biologii Doświadczalnej im. M. Nenckiego PAN Instytut Medycyny Doświadczalnej i Klinicznej PAN Isntytut Biocybernetyki i Inżynierii Biomedycznej PAN Instytut Podstawowych Problemów Techniki PAN

Project co-financed by the European Union from the European Social Fund within the Human Capital Operational Programme 2007-2013
Niniejszy serwis nie zbiera w sposób automatyczny żadnych informacji, za wyjątkiem informacji zawartych w plikach cookies. Przez używanie stron niniejszego serwisu wyrażasz zgodę na używanie ciasteczek zgodnie z naszą polityką. Jeżeli nie zgadzasz się na stosowanie cookies przez nasz serwis, powinieneś zmienić ustawienia swojej przeglądarki w odpowiedni sposób lub zrezygnować z używania stron tej witryny. X